These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 23933924)
1. Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case. Rao J; Feng M; Qian X; Li G; Wang X; Zhang F; Lu L Hepatogastroenterology; 2013 Sep; 60(126):1317-9. PubMed ID: 23933924 [TBL] [Abstract][Full Text] [Related]
2. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808 [TBL] [Abstract][Full Text] [Related]
3. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944 [TBL] [Abstract][Full Text] [Related]
4. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Frenette CT; Boktour M; Burroughs SG; Kaseb A; Aloia TA; Galati J; Gaber AO; Monsour H; Ghobrial RM Transpl Int; 2013 Jul; 26(7):734-9. PubMed ID: 23701126 [TBL] [Abstract][Full Text] [Related]
5. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity and sorafenib: a case report. García-Lledó J; Cortejoso L; Tenorio Núñez M; Giménez-Manzorro A; Matilla-Peña A; Salcedo-Plaza M; Sanjurjo-Sáez M Am J Ther; 2014; 21(5):e169-70. PubMed ID: 23676342 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity? Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739 [No Abstract] [Full Text] [Related]
10. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma. Park H; Han SH; Kang H; Park K Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299 [No Abstract] [Full Text] [Related]
11. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. Kashima T; Ohno Y; Tachibana M Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573 [No Abstract] [Full Text] [Related]
12. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785 [TBL] [Abstract][Full Text] [Related]
14. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy. Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291 [No Abstract] [Full Text] [Related]
15. Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib. Li ZY; Fan XX; Wang YJ; Yao K; Liu ZW; Pan WT; Ye YL; Yang P; Huang YC; Wu ZM; Zhou FJ Oncotarget; 2016 Jun; 7(23):35181-7. PubMed ID: 27174916 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy. Hung CT; Chiang CP; Wu BY J Dermatol; 2012 Dec; 39(12):1076-7. PubMed ID: 22724918 [No Abstract] [Full Text] [Related]
17. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic drugs and cardiogenic shock: a case report. Cortejoso L; García-Lledó J; Giménez-Manzorro A; Salcedo-Plaza M; Matilla-Peña A; Sanjurjo-Sáez M Am J Ther; 2014; 21(5):e163-5. PubMed ID: 23344105 [TBL] [Abstract][Full Text] [Related]